340B Update: Where We Are and Where We're Headed
The 340B environment has continued to evolve, and this year has been particularly busy as the drug pricing program is targeted and challenged. Covered Entities (CEs) and other professionals are invited to join us for an update on federal and state regulatory and legislative activity along with a discussion on the administrative dispute resolution process, Medicare Advantage payer litigation, and how CEs can continue to maintain a compliant 340B program despite these challenges.
Attendees learned more about the latest challenges to the 340B drug pricing program and how you can maintain a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.